PT  - JOURNAL ARTICLE
AU  - J-P Gutzwiller
AU  - B Göke
AU  - J Drewe
AU  - P Hildebrand
AU  - S Ketterer
AU  - D Handschin
AU  - R Winterhalder
AU  - D Conen
AU  - C Beglinger
TI  - Glucagon-like peptide-1: a potent regulator of food intake in humans
AID  - 10.1136/gut.44.1.81
DP  - 1999 Jan 01
TA  - Gut
PG  - 81--86
VI  - 44
IP  - 1
4099  - http://gut.bmj.com/content/44/1/81.short
4100  - http://gut.bmj.com/content/44/1/81.full
SO  - Gut1999 Jan 01; 44
AB  - Background/Aims Studies in animals suggest a physiological role for glucagon-like peptide-1-(7–36)-amide (GLP-1) in regulating satiety. The role of GLP-1 in regulating food intake in man has, however, not been investigated.Subjects—Sixteen healthy male subjects were examined in a double blind placebo controlled fashion.Methods The effect of graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) of synthetic human GLP-1 on food intake and feelings of hunger and satiety was tested in healthy volunteers.Results Graded GLP-1 infusions resulted in a dose dependent reduction in food intake (maximal inhibition 35%, p<0.001 vcontrol) and a similar reduction in calorie intake (32%; p<0.001). Fluid ingestion was also reduced by GLP-1 (18% reduction, p<0.01). No overt side effects were produced by GLP-1, but subjects experienced less hunger and early fullness in the period before a meal during GLP-1 infusion at the highest dose (p<0.05).Conclusions Intravenous infusions of GLP-1 decrease spontaneous food intake even at physiological plasma concentrations, implying an important role for GLP-1 in the regulation of the early satiety response in humans.GLP-1glucagon-like peptide-1CCKcholecystokinin